Tripod Therapeutics

Tripod Therapeutics is a pre-clinical stage biotechnology company focused on developing a new class of cancer therapeutics that target the DNA replication machinery. The company's proprietary platform identifies small molecule inhibitors that simultaneously target three essential DNA polymerases (alpha, delta, and epsilon), a strategy designed to overcome the resistance mechanisms often seen with single-target inhibitors. By disrupting the core replication complex, Tripod aims to induce catastrophic DNA damage specifically in cancer cells while sparing healthy tissue. Their lead programs are currently being evaluated for the treatment of various hard-to-treat solid tumors.